ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0883
0,08%
Bitcoin
67.048,72
1,34%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Circio Holding Asa (0RIS)

  7. Circio Holding Asa (0RIS) News

0RIS

Circio Holding Asa (0RIS)

Circio Holding Asa
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0RIS
DatumZeitQuelleÜberschriftSymbolFirma
28/02/202207h28PR Newswire (US)Targovax ASA strengthens management with Lubor Gaal as Chief Financial OfficerLSE:0RISCircio Holding Asa
28/02/202207h27PR Newswire (US)Targovax ASA strengthens management with Lubor Gaal as Chief Financial OfficerLSE:0RISCircio Holding Asa
12/01/202212h11PR Newswire (US)Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation NorwayLSE:0RISCircio Holding Asa
12/01/202212h09PR Newswire (US)Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation NorwayLSE:0RISCircio Holding Asa
20/12/202108h17PR Newswire (US)Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesotheliomaLSE:0RISCircio Holding Asa
20/12/202108h14PR Newswire (US)Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesotheliomaLSE:0RISCircio Holding Asa
04/11/202107h35PR Newswire (US)Targovax ASA: Third quarter 2021 resultsLSE:0RISCircio Holding Asa
04/11/202107h28PR Newswire (US)Targovax ASA: Third quarter 2021 resultsLSE:0RISCircio Holding Asa
25/10/202113h48PR Newswire (US)Targovax: Presentation material for today's webcastLSE:0RISCircio Holding Asa
25/10/202113h47PR Newswire (US)Targovax: Presentation material for today's webcastLSE:0RISCircio Holding Asa
20/10/202108h50PR Newswire (US)Targovax ASA appoints Dr. Erik Digman Wiklund as new CEOLSE:0RISCircio Holding Asa
20/10/202108h48PR Newswire (US)Targovax ASA appoints Dr. Erik Digman Wiklund as new CEOLSE:0RISCircio Holding Asa
19/10/202114h27PR Newswire (US)Targovax to present at upcoming conferencesLSE:0RISCircio Holding Asa
19/10/202114h24PR Newswire (US)Targovax to present at upcoming conferencesLSE:0RISCircio Holding Asa
06/10/202115h00PR Newswire (US)Targovax ASA: Two abstracts accepted at the SITC CongressLSE:0RISCircio Holding Asa
06/10/202114h51PR Newswire (US)Targovax ASA: Two abstracts accepted at the SITC CongressLSE:0RISCircio Holding Asa
30/09/202107h49PR Newswire (US)Targovax ASA appoints Ola Melin as Head of ManufacturingLSE:0RISCircio Holding Asa
30/09/202107h42PR Newswire (US)Targovax ASA appoints Ola Melin as Head of ManufacturingLSE:0RISCircio Holding Asa
24/09/202111h19PR Newswire (US)Targovax granted European Patent for ONCOS-102 in combination with chemotherapyLSE:0RISCircio Holding Asa
24/09/202111h17PR Newswire (US)Targovax granted European Patent for ONCOS-102 in combination with chemotherapyLSE:0RISCircio Holding Asa
16/09/202107h42PR Newswire (US)Targovax ASA: Poster at European Society for Medical Oncology (ESMO)LSE:0RISCircio Holding Asa
16/09/202107h41PR Newswire (US)Targovax ASA: Poster at European Society for Medical Oncology (ESMO)LSE:0RISCircio Holding Asa
27/08/202109h17PR Newswire (US)Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO CongressLSE:0RISCircio Holding Asa
27/08/202109h15PR Newswire (US)Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO CongressLSE:0RISCircio Holding Asa
18/08/202107h57PR Newswire (US)Targovax ASA: second quarter and first half year 2021 resultsLSE:0RISCircio Holding Asa
18/08/202107h55PR Newswire (US)Targovax ASA: second quarter and first half year 2021 resultsLSE:0RISCircio Holding Asa
16/08/202107h48PR Newswire (US)Targovax to present at upcoming scientific conferencesLSE:0RISCircio Holding Asa
09/08/202107h14PR Newswire (US)Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 AugustLSE:0RISCircio Holding Asa
09/08/202107h13PR Newswire (US)Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 AugustLSE:0RISCircio Holding Asa
01/07/202111h11PR Newswire (US)Targovax ASA appoints Dr Lone Ottesen as Chief Development OfficerLSE:0RISCircio Holding Asa
 Showing the most relevant articles for your search:LSE:0RIS

Kürzlich von Ihnen besucht

NASDAQ
GGUY
Good Guys
ASX
PRS
Prospech
NASDAQ
IAAHRX
Investment Grade Municip...
NASDAQ
FGUAEX
Global Dividend Portfoli...
EU
3193T
3193T
LSE
JUDS
Jpm Act Us Eq D
COIN
DGGETH
DeGate Token
KUCN
IHCUSDT
Inflation Hedging Coin
NYSE
CRY
CryoLife
LSE
KESG
Mcsi Ch Esg Usd
AMEX
BAD
Bad ETF
LSE
LCA
ASX
INE
India Equities Fund
EU
H867T
H867T
COIN
KSOCUSD
KickSoccer Coin
KOSPI
001470
Sambu Engineering and Co...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten